Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics
Article content
Article content
– Patient dosing is underway in the Phase 3 CYB003 PARADIGM program in Major Depressive Disorder ('MDD') with expected combined enrollment of approximately 550 participants across three studies (APPROACH™, EMBRACE™, and EXTEND) –
Article content
Article content
– Partnerships with Osmind and Thermo Fisher Scientific strengthen the Company's commercialization and manufacturing capabilities –
Article content
– Positive regulatory signals from U.S. Agencies amid expanding media coverage could expedite regulatory pathways across Cybin's clinical-stage pipeline –
Article content
TORONTO — Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today provided a corporate update.
Article content
'It is especially gratifying that at a time when we are advancing our clinical pipeline programs, with our lead program CYB003 in Phase 3 development, the path toward approval and eventual commercialization of psychedelic therapeutics is gaining clarity,' said Doug Drysdale, Chief Executive Officer of Cybin. 'With our expanded intellectual property portfolio, and a number of key partnerships in place, we believe our rigorous research and novel clinical approach can lead to a transformation in how mental health disorders are treated. Now is the time to address the mental health crisis, and we are encouraged by recent sentiment in favor of expediting the regulatory review process for product candidates in development.'
Article content
Continued to expand its strategic clinical site partnership ('SPA') program in support of the Phase 3 PARADIGM program. The SPA program is designed to facilitate collaboration among sites, enhance efficiency in trial operations, and improve overall site performance.
Partnered with Thermo Fisher Scientific, a world-class manufacturing partner, to provide U.S.-based manufacturing for the CYB003 program. Cybin broadened its existing strong relationship with Thermo Fisher Scientific to include the development of both the drug substance and drug product capsules for CYB003.
Partnered with Osmind, a leading service provider to psychiatry practices in the U.S., with the objective of accelerating commercial preparation for clinical-stage pipeline. Osmind advances psychiatry through technology and services to bring innovative mental health treatments to patients in need. Cybin will leverage Osmind's 800-clinic network, point-of-care software, and real-world data to support commercial preparation for its clinical-stage pipeline.
Continued to expand intellectual property portfolio with two additional U.S. patents supporting lead programs CYB003 and CYB004, bringing the total to over 90 granted patents and over 230 pending applications. The recently issued patents are as follows:
U.S. patent 12,291,499 includes pharmaceutical compositions and oral dosage forms within the CYB003 program with expected exclusivity until 2041.
U.S. patent 12,318,477 is expected to provide exclusivity until 2040 and includes claims to novel formulations of DMT and deuterated isotopologues for intramuscular ('IM') injection, including CYB004.
Article content
Positive Regulatory Signals and Evolving Acceptance of Potential Therapeutic Value of Psychedelics
Article content
Recent statements and hiring decisions by senior U.S. Health and Human Services ('HHS') and FDA officials, in addition to ongoing signs of bipartisan congressional support, suggest an improved forward regulatory environment for psychedelic medicine and therapies, including the potential for accelerated approval pathways.
Article content
The Company believes that these developments, together with increased political recognition and public understanding of the science underpinning these programs, have the potential to expedite regulatory pathways and reduce overall risk across its clinical portfolio. Highlights include:
Article content
In a recent interview, FDA Commissioner Dr. Marty Makary stated that psychedelic-drug review is a 'top priority' and promised an 'expeditious and rapid review' of clinical data. 1
Article content
Drug-policy lawyer, Matthew Zorn, has joined HHS as Deputy General Counsel to work on psychedelics policy. He previously challenged the government on matters such as allowing research on cannabis for veterans with PTSD, preventing tryptamines from being scheduled, and fighting for patient access to psilocybin under Right to Try laws. 2
Article content
Navy-SEAL-turned-Congressman Morgan Luttrell recently urged the GOP to 'embrace' compounds such as psilocybin, MDMA and ibogaine to help veterans with PTSD. 3
Article content
President Trump's new pick for surgeon general, Dr. Casey Means, wrote in a recent book that people should consider guided-psychedelic therapy. 4
Article content
On June 19, 2025, Doug Drysdale will speak in a panel discussion focused on the regulatory landscape and next steps for potential commercialization, at the Psychedelic Science 2025 Conference taking place June 16-20, 2025, in Denver, Colorado. The panel details are as follows:
Article content
Panel Title:
Article content
Date and Time:
Article content
About Cybin
Article content
Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.
Article content
With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds.
Article content
Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.
Sources
Article content
NewsNation, 'FDA Commissioner Says Research on Psychedelic Treatment 'Top Priority',' interview with FDA Commissioner Dr. Marty Makary, video posted May 16, 2025, https://www.youtube.com/watch?v=KEQFKBME668 (accessed June 9, 2025).
Politico, 'A Psychedelics Hire at HHS,' newsletter article, published May 28 2025, https://www.politico.com/newsletters/future-pulse/2025/05/28/a-psychedelics-hire-at-hhs-00371416 (accessed June 9 2025).
The Wall Street Journal, 'Lawmaker 'Reborn' Through Psychedelic Therapy Wants the GOP to Embrace It,' news article, published May 17 2025, https://www.wsj.com/politics/policy/republican-psychedelic-drug-therapy-fc313ea2 (accessed June 9 2025).
The Associated Press, 'Trump Surgeon General Pick Praised Unproven Psychedelic Therapy, Said Mushrooms Helped Her Find Love,' news article, published May 14 2025, https://apnews.com/article/means-trump-surgeon-general-mushrooms-psychedelic-drugs-72c22ed077409b4bb865214e7ef304a8 (accessed June 9 2025).
Fox News. 'Trump Administration Exploring Potential Benefits of Psychedelic Treatments.' America's Newsroom, correspondent Alexandria Hoff, broadcast June 5 2025. Video clip, 1:58. https://www.foxnews.com/video/6373914669112
Article content
Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, 'forward-looking statements') and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'potential', 'possible', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's plans to enroll participants and add additional clinical sites for the PARADIGM program; regulatory statements that suggest an expedited regulatory pathway for Cybin programs; the anticipated approval and commercialization of CYB003 and CYB004; the ability to accelerate commercial preparation of clinical-stage programs through the Company's partnership with Osmind; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.
Article content
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company's annual information form for the year ended March 31, 2024, which are available under the Company's profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov/edgar. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Article content
Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Investor & Media:
Article content
Article content
Gabriel Fahel
Article content
Article content
Chief Legal Officer
Article content
Article content
Cybin Inc.
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
35 minutes ago
- CBC
Airbnb says thousands of B.C. reservations at risk, blames 'rushed' rental rules
Short-term vacation rental platform Airbnb said Friday that "thousands" of reservations in British Columbia are at risk of cancellation, accusing the province of rushing out regulations as it cracked down on the industry. Alex Howell, Airbnb's Canadian policy lead, said in an interview with The Canadian Press that the new rules, which require short-term rental hosts to confirm their listings are legal, have already led to some bookings being cancelled. The government has said platforms such as Airbnb can't post B.C. listings without confirming they are registered with the province. Howell said many hosts whose properties qualify can't register due to glitches and other problems with the new system. "Typically, we would have worked with a government for six months to do live testing, to make sure that things are working the way they should," Howell said. "And unfortunately in this situation, B.C. really just rushed into launching the system that hadn't been fully tested, and that's what's brought us to this situation." The province said Friday that dozens of other short-term rental platforms serving B.C. have managed to support their hosts in registering with the government. But Howell said that property owners have reported that typos and formatting errors have prevented them from registering with the province, despite meeting all the legal criteria for hosting short-term rentals. "The government's short-term rental system simply isn't ready," Howell said in a statement to CBC News. "We warned that rushing this rollout would lead to serious consequences, and now British Columbians are paying the price." Summer is tourist season The province had said that short-term rentals are being restricted to principal residences, a secondary suite or a structure such as a laneway house on the property, and the policy is meant to open up more units in B.C.'s rental housing market. Howell said the timing of B.C.'s latest rules on short-term rentals is especially impactful, just ahead of the busy summer tourist season. "Thousands of reservations across the province are now at risk," she said. "These are registered, compliant hosts that are failing validation protocols through no fault of their own. "And this impacts … thousands of reservations across the province, at least 50 per cent of which are domestic travellers who are following their own government's advice to support local and travel within Canada this year." Howell said instead of waiting until the June 23 deadline — when bookings on unregistered B.C. properties would be cancelled — Airbnb is proactively contacting affected hosts and guests to offer penalty-free cancellations. Airbnb can 'find solutions' In a statement, B.C. Housing Minister Ravi Kahlon said the province is confident that "Airbnb will find solutions to their challenges with getting listings verified ahead of the June 23 deadline." "We hope that Airbnb will choose to support their hosts in verifying their listings, instead of cancelling their bookings," Kahlon said. "This is new ground for B.C., and we are working through ServiceBC, our short-term rental branch, and the platforms themselves to help hosts comply with the requirements." The ministry also noted that there are 65 short-term rental platforms operating in B.C., and other platforms have been successful in supporting their hosts to get registered. In a separate statement, the Opposition B.C. Conservatives criticized the NDP's short-term rental policies, with Prince George-Valemount MLA Rosalyn Bird saying the regulations run counter to the province's efforts to promote local travel. "How do you promote staycations while sabotaging the short-term rental market that makes them possible in small towns?" Bird said in the statement. "The Premier [David Eby] says 'travel within B.C.', and then his government kneecaps our ability to welcome those travellers."
CTV News
2 hours ago
- CTV News
Streets Alive Mission set out to raise $70,000 with inaugural Giving Day
Streets Alive Mission set out to raise $70,000 in just one day on Friday in support of its programs and services. Streets Alive Mission set out to raise $70,000 in just one day on Friday in support of its programs and services. Throughout the day, staff have been at the Christian Credit Union along Mayor Magrath Drive South collecting donations. This is the first year the mission has hosted a Giving Day. Last year, Streets Alive served more than 2,000 people, from providing basic needs to life recovery programming. Two anonymous donors have come forward to match dollars raised. Staff say without the community support, the mission wouldn't be able to operate. 'Each dollar really impacts a life. It really changes a life,' said Jennifer Lepko, Streets Alive Mission chief development officer. 'Streets Alive helps people from the streets and gets them up into recovery, changing their lives. 'It's really a life recovery program and it gets them back into community and fleeing from some of the addiction issues and the poverty that they experience.' Streets Alive Mission set out to raise $70,000 in just one day on Friday in support of its programs and services. Streets Alive Mission set out to raise $70,000 in just one day on Friday in support of its programs and services. While staff hoped to raise $70,000 on Friday, they say donations of time, items and money are kindly accepted year-round. Streets Alive's next event is the fourth annual Wing Ding wing-eating contest. The event, sponsored by Save-On-Foods, will take place June 28 from noon to 5 p.m., at the Nicholas Sheran Park picnic shelter in West Lethbridge. The wing-eating contest itself is at will be at 2 p.m. 'How many wings can YOU eat in 60 seconds? Challenge yourself and raise funds for Streets Alive Mission,' Streets Alive says on its website.
CBC
3 hours ago
- CBC
Regina Urgent Care Centre to close early Saturday
Social Sharing Regina's only urgent care centre will close its doors five and a half hours early Saturday, at 4 p.m. CST. The Saskatchewan Health Authority (SHA) announced the change in hours on Friday, saying the centre's regular 9:30 p.m. close time will resume on Sunday. The province did not provide a reason for the reduced hours in its initial announcement. It asked people to go to Regina General Hospital or Pasqua Hospital if they experience a medical emergency during the centre's early closure. The care centre acts as an alternative to hospital emergency rooms, treating non-life-threatening illnesses and injuries, and providing mental health support. When it opened in July 2024, it was Saskatchewan's first urgent care centre. The government said the centre would transition to a 24/7 model by fall, but that promise has yet to be fulfilled. In response to this weekend's reduced hours, the Opposition NDP called for the Saskatchewan Party to better fund health care and properly staff the Regina Care Centre. "The Sask. Party says it's building more urgent care centres, but it can't even staff the centre that is already open," an NDP statement said. The centre previously temporarily reduced its hours in December 2024.
